Current Report Filing (8-k)
16 Mars 2023 - 5:11PM
Edgar (US Regulatory)
0001368620
false
0001368620
2023-01-30
2023-01-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 30, 2023
Cann American
Corp
(Exact name of registrant as specified in its charter)
| Wyoming |
000-53712 |
84-3208139 |
| (State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
| of Incorporation) |
File Number) |
Identification No.) |
75
Union Ave., Rutherford, NJ 07070
(Address of Principal Executive Offices) (Zip Code)
(551) 285-4350
(Registrant’s telephone number, including
area code)
320 Santana Drive #C, Cloverdale, CA 95425
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| N/A |
N/A |
N/A |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On January 30, 2023, the Company entered into
a Binding Letter of Intent to acquire Prodigy Stem Cell, LLC as a wholly owned subsidiary of the Company.
Item
2.01 Completion of Acquisition or Disposition of Assets.
On March 1, 2023, the Company completed the acquisition of Prodigy
Stem Cell, LLC as a wholly owned subsidiary. Prodigy Stem Cell, LLC is a New Jersey based company focused on sales, marketing, and consulting
for regenerative medicines.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On March 1, 2023, the Company appointed Peter Caruso as a Director
of the Company. Mr. Caruso has over 20 years of business development experience and is the Founder of Prodigy Stem Cell, LLC.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly
authorized.
| |
Cann American Corp |
| |
|
| |
By: |
/s/ Jason Tucker |
| |
|
Jason Tucker
CEO |
Date:
March 16, 2023
Cann American (CE) (USOTC:CNNA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cann American (CE) (USOTC:CNNA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
